Table 2.
Real-world best tumor responses.
| Response |
Unadjusted |
sIPTW |
||||
|---|---|---|---|---|---|---|
|
Letrozole (n = 406) |
Palbociclib + Letrozole (n = 390) |
P Value |
Letrozole (n = 335) |
Palbociclib + Letrozole (n = 450) |
P Value | |
| CR | 17 (4.2) | 32 (8.2) | <0.001 | 13 (4.0) | 45 (10.1) | <0.001 |
| PR | 70 (17.2) | 171 (43.8) | 60 (18.0) | 190 (42.3) | ||
| Stable disease | 53 (13.1) | 86 (22.1) | 44 (13.0) | 98 (21.8) | ||
| Progressive disease | 68 (16.8) | 47 (12.1) | 52 (15.6) | 57 (12.7) | ||
| Indeterminate | 13 (3.2) | 8 (2.1) | 10 (3.0) | 7 (1.6) | ||
| Missing | 185 (45.6) | 46 (11.8) | 155 (46.4) | 52 (11.5) | ||
| Best overall response (CR + PR) | 87 (21.4) | 203 (52.1) | <0.001 | 74 (22.1) | 236 (52.4) | <0.001 |
CR = complete response; PR = partial response; sIPTW = stabilized inverse probability treatment weighting.
All data are n (%) unless otherwise noted.